טוען...
Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience
BACKGROUND: The aim of our study was to evaluate the safety and efficacy of triple therapy using boceprevir (BOC) with pegylated interferon (pIFN)/ribavirin (RBV) in chronic hepatitis C (CHC) genotype 1 (G1) treatment-experienced patients with advanced fibrosis or compensated cirrhosis. METHODS: We...
שמור ב:
הוצא לאור ב: | Ann Gastroenterol |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Hellenic Society of Gastroenterology
2015
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4585396/ https://ncbi.nlm.nih.gov/pubmed/26423714 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|